Preimplantation Genetic Diagnosis Market - Asia Industry Analysis, Size, Share, Growth, Trends, And Forecast Up To 2023

The market overview section of the report demonstrates major market dynamics such as drivers, restraints, and opportunities that influence the current and future status of the industry. The market overview section includes Porter’s Five Forces Analysis, overview of PGD, Regulatory Policies and Legality Framework for PGD, Heat Map Analysis for key market players, and country-wise number of PGD Centers in Asia. The report provides a detailed industry analysis of the preimplantation genetic diagnosis (PGD) market in Asia with the help of market attractiveness analysis, by geography, for the year 2014.

For Any Queries Get Solutions With A PDF Sample : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9989

The market has been analyzed for Asia covering South Eastern Asia, Eastern Asia, Southern Asia, Central Asia, and Western Asia. The market size and forecast of the regional and country-wise markets is provided for the period 2013 to 2023. CAGR (%) for each region is also estimated for the period 2015 to 2023, considering 2014 as the base year. South Eastern Asia includes Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Rest of SEA. Eastern Asia comprises China, Japan, South Korea, and Rest of Eastern Asia. Southern Asia constitutes India, Sri Lanka, and Rest of Southern Asia. Western Asia includes Israel, Turkey, Jordan, Saudi Arabia, the United Arab Emirates, and Rest of Western Asia. Eastern Asia accounted for the largest share of the PGD market in Asia.

The report also provides recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market shares and help new companies to establish their presence in the PGD market in Asia. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments. Major players in this market are Genesis Genetics (U.S.), Genea Limited (Australia), Illumina, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc.(U.S.), Quest Diagnostics Incorporated (U.S.), Reprogenetics (U.S.), and Reproductive Genetics Innovations LLC (U.S.). The market share analysis of key players involved the study of company products or services portfolio, post sales services and maintenance, sales revenue, and its geographical presence.

The preimplantation genetic diagnosis (PGD) market in Asia has been segmented based on test type, end-user, and geography. Based on test type, the market has been segmented into aneuploidy screening, chromosomal aberrations, gender selection, HLA typing, single gene disorder, and X-linked diseases. The market analysis is based on market size and forecast in terms of US$ Mn for the period 2013 to 2023 along with the compound annual growth rate (CAGR %) for the period 2015 to 2023, considering 2014 as the base year. The aneuploidy screening segment accounted for the largest share of 35% of the PGD market in Asia in 2014. Based on end-user, the market has been segmented into fertility clinics, health care facilities (including hospitals, diagnostic centers, and health care facilities), and academic institutes and research centers.

Preimplantation genetic diagnosis (PGD) is the inspection of an embryo in vitro in order to eliminate a genetic condition in case a high risk of that condition is known. PGD is an evolving technique that provides a practical alternative to prenatal diagnosis and termination of pregnancy for couples who are at substantial risk of transmitting a serious genetic disorder to their offspring. Growing incidence of infertility across the world is the major driver of the PGD market. Preimplantation genetic diagnosis plays an important role in the detection and determination of genetic disorders, sex-linked diseases, and chromosomal abnormalities in the embryo before IVF can be performed. Rising incidence of infertility coupled with growing awareness about IVF and PGD is the major factor driving the PGD market in Asia.

Rising numbers of assisted reproductive procedures such as in vitro fertilization (IVF) is Asia is the most prominent factor driving the market for preimplantation genetic diagnosis. This is, in essence, the result of factors such as the delayed age of conception among Asian women, the rising rate of infertility among the population, and the significantly expanding medical tourism industry in the region. Rising disposable incomes and increased awareness regarding the rising prevalence of a number of genetic disorders are also encouraging the Asian population to undertake costly diagnostic procedures such as PGD.

View exclusive Global strategic Business report : http://www.transparencymarketresearch.com/asia-preimplantation-genetic-diagnosis-market.html

TMR analysts project that these factors will enable the Asia preimplantation genetic diagnosis market expansion at a healthy 6.8% CAGR from 2015 to 2023. The market is expected to rise from a valuation of US$16.0 mn in 2014 to US$28.8 mn by 2023.

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: : http://www.transparencymarketresearch.com/

This release was published on openPR.